Brief: Aquestive Therapeutics Receives Conditional FDA Acceptance Of Proprietary Name Anaphylm™ For Lead Candidate Aqst-109 (Epinephrine Sublingual Film)
20/04/2023 13:04
April 20 (Reuters) - Aquestive Therapeutics Inc
AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES CONDITIONAL FDA ACCEPTANCE
OF
PROPRIETARY NAME ANAPHYLM™ FOR LEAD CANDIDATE AQST-109
(EPINEPHRINE SUBLINGUAL FILM)
Source text for Eikon: ID:nGNX6lsY6w
Further company coverage: AQST.O
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million